NewsMakers9 years ago
FDA grants priority review for Lilly’s abemaciclib for breast cancer treatment
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase...
